The future of tertiary lymphoid structures in cancer immunotherapy as biomarkers and therapeutic targets

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

► Unclassified Cookies Remark

Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.

Teclistamab/Talquetamab Hits Record Low Hazard Ratio in Multiple Myeloma